Tapering Antipsychotic Medication in Patients with Severe Mental Disorders

Rationale and Approach

The American Academy of Child and Adolescent Psychiatry recommends gradually tapering risperidone over 2-4 weeks by reducing the dose by 25% every 1-2 weeks, while discontinuing adjunctive medications, to avoid withdrawal symptoms and rebound worsening of psychotic and manic symptoms in patients with schizophrenia and bipolar disorder 1, 2
When a patient is on multiple medications, the medication used adjunctively should be removed first, while maintaining the medication with the most prophylactic efficacy for the underlying severe disorder, according to the American Academy of Child and Adolescent Psychiatry 1

A gradual tapering schedule is recommended, with a 25% reduction in risperidone dose every 1-2 weeks, to minimize the risk of withdrawal symptoms and rebound psychosis, as suggested by clinical guidelines 3
The tapering schedule may need to be adjusted based on the patient's response, with a possible extension of each reduction phase by 1-2 weeks if severe psychotic or manic symptoms emerge, according to the American Academy of Child and Adolescent Psychiatry 5

Close monitoring is necessary during the tapering process to detect potential withdrawal symptoms, such as anxiety, insomnia, and irritability, which typically emerge within days, as well as psychotic and manic symptoms, according to clinical guidelines 4, 5
The patient's previous medication should not be started until risperidone is completely discontinued, to avoid antipsychotic polypharmacy, unless specifically justified, as recommended by the American Academy of Child and Adolescent Psychiatry 4

In patients with complex diagnostic pictures, such as schizophrenia, bipolar disorder, and major depressive disorder, the underlying psychotic disorder should remain the treatment priority, according to the American Academy of Child and Adolescent Psychiatry 1
Risperidone is FDA-approved for both schizophrenia and bipolar mania, making it an appropriate treatment option for patients with these conditions, as noted by the American Academy of Child and Adolescent Psychiatry 2